Autologous Transplant in HIV Patients (BMT CTN 0803)

ClinicalTrials.gov ID: NCT01141712

Public ClinicalTrials.gov record NCT01141712. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

High Dose Chemotherapy With Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients (BMT CTN #0803)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is a Phase II, multicenter trial assessing overall survival after autologous hematopoietic stem cell transplantation using a BEAM transplant regimen (carmustine, etoposide, cytarabine, melphalan) in lymphoma patients with HIV.

Study identification

NCT ID: NCT01141712
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Medical College of Wisconsin; Other
Enrollment: 43 participants

Conditions and interventions

Conditions

Interventions

Procedure · Drug

Eligibility (public fields only)

Age range: 15 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2010 (Type not available)
Primary completion: May 2015 (Actual)
Completion: Jun 2016 (Actual)
Last update posted: Jan 4, 2023

2010 – 2016

United States locations

U.S. sites: 16
U.S. states: 8
U.S. cities: 13

Facility	City	State	ZIP	Site status
City of Hope National Medical Center	Duarte	California	91010-3000	—
University of California San Diego Medical Center	La Jolla	California	92093	—
UCLA	Los Angeles	California	90035	—
University of CA, SF	San Francisco	California	94143	—
University of Florida College of Medicine	Gainesville	Florida	32610	—
H. Lee Moffitt Cancer Center	Tampa	Florida	33624	—
Emory University	Atlanta	Georgia	30322	—
BMT Program at Northside Hospital	Atlanta	Georgia	30342	—
University of Maryland Medical Systems, Greenebaum Cancer Center	Baltimore	Maryland	21201	—
Johns Hopkins Medical Institution	Baltimore	Maryland	21231	—
Washington University/Barnes Jewish Hospital	St Louis	Missouri	63110	—
Weill Cornell Medical College	New York	New York	10065	—
Memorial Sloan-Kettering Cancer Center	New York	New York	10174	—
University of Rochester	Rochester	New York	14642	—
Ohio State University Medical Center	Columbus	Ohio	43210	—
University of Texas/MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01141712, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 4, 2023 · Synced Oct 26, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01141712 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →